Tags |
|
|
Links |
|
|
Digg It - Creativity and Innovation - Large Firms Versus Small Firms
There is a pervasive assumption that small firms are more creative and innovative than larger firms. That is,
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
they identify problems and generate ideas (creativity) and idea select, develop and commercialise (innovate)
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
those ideas to a greater degree than larger firms. However, there is a large degree of untruth to this assum
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
ption:
a) Small firms suffer from a different set of problems than larger firms. Small firms, for example, t
a) Small firms suffer from a different set of problems than larger firms. Small firms, for example, t
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
end to lack resources whereas larger firms tend to have more resources but may be less ready for wholesale ad
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
aptation in times of radical change. But these limitations do not mean that one is more innovative than the o
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
ther. The sheer availability of resources means larger firms should be able to innovate along product, proces
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
s, positioning and paradigm lines more often.
b) Large firms register more patents than small firms.
c) Rel
b) Large firms register more patents than small firms.
c) Rel
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
atively little data is available about innovation in small firms.
d) Most research of small firms has been c
d) Most research of small firms has been c
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
onducted in the technology sector – a very small sample with it’s own idiosyncrasies – the very large investm
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
nts that some tech firms get skews the data.
e) There is little data analysing whether the innovations produ
e) There is little data analysing whether the innovations produ
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
ced by small firms has any significance at all.
f) Small firms will inevitably tend to suffer a lack of inte
f) Small firms will inevitably tend to suffer a lack of inte
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
llectual cross-pollination and frame breaking and higher degrees of path dependency and parochialism.
g) The
g) The
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
re is confusion between organisational size and team size. Small teams working with direct access to decision
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
makers in large organisations can be just, if not more (with larger resources), effective than small firms.
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
These and other topics are covered in depth in the MBA dissertation on Managing Creativity & Innovation, whi
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
ch can be purchased (along with a Creativity and Innovation DIY Audit, Good Idea Generator Software and Power
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
Point Presentation) from http://www.managing-creativity.com/
You can also receive a regular, free newslette
You can also receive a regular, free newslette
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
r by entering your email address at this site.
Kal Bishop, MBA
**********************************
You are
Kal Bishop, MBA
**********************************
You are
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
free to reproduce this article as long as no changes are made and the author's name and site URL are retained
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.diggit.org.ua/article/24070/diggit-Creativity-and-Innovation--Large-Firms-Versus-Small-Firms.html">Creativity and Innovation - Large Firms Versus Small Firms</a>
BB link (for phorums):
[url=http://www.diggit.org.ua/article/24070/diggit-Creativity-and-Innovation--Large-Firms-Versus-Small-Firms.html]Creativity and Innovation - Large Firms Versus Small Firms[/url]
Related Articles:
We Must Think Invest For Every Think We Do
Business Management Case Study; How the Modern-Day Franchise Model Is Being Abused
Reporting is Serious Business!
Bookmark it:
|